JP2006510619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006510619A5 JP2006510619A5 JP2004554020A JP2004554020A JP2006510619A5 JP 2006510619 A5 JP2006510619 A5 JP 2006510619A5 JP 2004554020 A JP2004554020 A JP 2004554020A JP 2004554020 A JP2004554020 A JP 2004554020A JP 2006510619 A5 JP2006510619 A5 JP 2006510619A5
- Authority
- JP
- Japan
- Prior art keywords
- box
- hmgb
- polypeptide
- group
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 46
- 229920001184 polypeptide Polymers 0.000 claims 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims 45
- 239000012634 fragment Substances 0.000 claims 43
- 101001005953 Homo sapiens Putative high mobility group protein B1-like 1 Proteins 0.000 claims 17
- 102100025288 Putative high mobility group protein B1-like 1 Human genes 0.000 claims 17
- 102000004127 Cytokines Human genes 0.000 claims 16
- 108090000695 Cytokines Proteins 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000000849 HMGB Proteins Human genes 0.000 claims 11
- 108010001860 HMGB Proteins Proteins 0.000 claims 11
- 230000000770 proinflammatory effect Effects 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 6
- 102000055207 HMGB1 Human genes 0.000 claims 6
- 108700010013 HMGB1 Proteins 0.000 claims 6
- 101150021904 HMGB1 gene Proteins 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 230000004913 activation Effects 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 5
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 4
- 108010008165 Etanercept Proteins 0.000 claims 4
- 229960002964 adalimumab Drugs 0.000 claims 4
- 229960003115 certolizumab pegol Drugs 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 229960000403 etanercept Drugs 0.000 claims 4
- 229960000598 infliximab Drugs 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 229960003433 thalidomide Drugs 0.000 claims 4
- 230000004071 biological effect Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 229950007278 lenercept Drugs 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010034674 peritonitis Diseases 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000016261 weight loss Diseases 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42784602P | 2002-11-20 | 2002-11-20 | |
| US42784102P | 2002-11-20 | 2002-11-20 | |
| PCT/US2003/037507 WO2004046345A2 (en) | 2002-11-20 | 2003-11-20 | Use of hmgb fragments as anti-inflammatory agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510619A JP2006510619A (ja) | 2006-03-30 |
| JP2006510619A5 true JP2006510619A5 (enExample) | 2006-12-28 |
Family
ID=32329191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004554020A Pending JP2006510619A (ja) | 2002-11-20 | 2003-11-20 | 抗炎症剤としてのｈｍｇｂ断片の使用 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1569684A4 (enExample) |
| JP (1) | JP2006510619A (enExample) |
| AU (1) | AU2003294488B2 (enExample) |
| CA (1) | CA2506328A1 (enExample) |
| NZ (1) | NZ540067A (enExample) |
| WO (1) | WO2004046345A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| WO2005025604A2 (en) * | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
| CA2882022A1 (en) | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| PT1768677E (pt) * | 2004-07-02 | 2008-10-06 | Creabilis Therapeutics Spa | Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1 |
| EP1814576A2 (en) * | 2004-07-20 | 2007-08-08 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| EP1797118A2 (en) * | 2004-09-03 | 2007-06-20 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
| WO2007001422A2 (en) * | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| WO2006138429A2 (en) * | 2005-06-16 | 2006-12-28 | The Feinstein Institute For Medical Research | Antibodies against hmgb1 and fragments thereof |
| US20100040608A1 (en) * | 2005-07-18 | 2010-02-18 | Marie Wahren-Herlenius | Use of HMGB1 antagonists for the treatment of inflammatory skin conditions |
| WO2007031100A1 (en) * | 2005-09-14 | 2007-03-22 | Ostini, Marco | Active immunotherapy of life-threatening systemic inflammation |
| AU2006312847A1 (en) * | 2005-11-09 | 2007-05-18 | Pharmexa A/S | Therapeutic vaccines targeting HMGB1 |
| CA2663300C (en) * | 2006-09-15 | 2014-10-07 | Creabilis Therapeutics S.P.A. | Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1 |
| ES2520026T3 (es) | 2006-09-18 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Composiciones y métodos para potenciar respuestas inmunitarias |
| US8470325B2 (en) | 2007-02-15 | 2013-06-25 | Kagoshima University | Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody |
| WO2009133943A1 (ja) | 2008-04-30 | 2009-11-05 | 株式会社ジェノミックス | 生体内機能的細胞の高効率採取法 |
| CN102711777B (zh) | 2009-10-28 | 2015-04-15 | 吉诺米克斯股份有限公司 | 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂 |
| CN102811734B (zh) | 2010-01-21 | 2016-02-10 | 阿肯色大学评议会 | 增强免疫应答的疫苗载体和方法 |
| CN102971008B (zh) | 2010-06-09 | 2015-11-25 | 阿肯色大学评议会 | 降低弯曲菌属感染的疫苗和方法 |
| DK2703487T3 (en) | 2011-04-26 | 2018-09-10 | Genomix Co Ltd | TIME TO INDUCTION Tissue Regeneration and its Use |
| EP2913059B1 (en) | 2012-10-25 | 2018-04-11 | Genomix Co., Ltd. | Novel method for treating spinal cord injury using hmgb1 fragment |
| RU2647467C2 (ru) | 2012-10-25 | 2018-03-15 | Дженомикс Ко., Лтд. | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 |
| MX2015009547A (es) | 2013-01-28 | 2015-11-25 | Evec Inc | Anticuerpo anti-hmgb1 humanizado o fragmento de union al antigeno del mismo. |
| US9603915B2 (en) | 2013-02-14 | 2017-03-28 | The Board of Trustees of the University of Akansas | Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection |
| BR112015023024B1 (pt) | 2013-03-15 | 2022-04-19 | The Board Of Trustees Of The University Of Arkansas | Vetor de vacina e composições farmacêuticas compreendendo o mesmo |
| KR102767638B1 (ko) | 2016-05-03 | 2025-02-20 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법 |
| BR112019014921A2 (pt) | 2017-01-27 | 2020-03-31 | StemRIM Inc. | Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica |
| EP3595445B1 (en) | 2017-03-15 | 2024-09-04 | The Research Institute at Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
| US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
| EP3719117A4 (en) | 2017-12-01 | 2021-11-03 | Stemrim Inc. | EECTODERMAL MESENCHYMAL STEM CELLS AND METHOD FOR PRODUCING THEM |
| US20210024594A1 (en) * | 2018-02-08 | 2021-01-28 | StemRIM Inc. | Therapeutic Agent for Psoriasis |
| US12304933B2 (en) | 2018-10-05 | 2025-05-20 | StemRIM Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
| EP3860718A4 (en) | 2018-10-05 | 2022-08-31 | Research Institute at Nationwide Children's Hospital | HMGB1 PROTEIN DERIVATIVES FOR BIOFILM REMOVAL |
| CN111743890A (zh) * | 2019-03-26 | 2020-10-09 | 深圳先进技术研究院 | 水绫霉素或其衍生物的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| CA2296792A1 (en) * | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
-
2003
- 2003-11-20 NZ NZ540067A patent/NZ540067A/en not_active IP Right Cessation
- 2003-11-20 EP EP03789973A patent/EP1569684A4/en not_active Withdrawn
- 2003-11-20 JP JP2004554020A patent/JP2006510619A/ja active Pending
- 2003-11-20 WO PCT/US2003/037507 patent/WO2004046345A2/en not_active Ceased
- 2003-11-20 CA CA002506328A patent/CA2506328A1/en not_active Abandoned
- 2003-11-20 AU AU2003294488A patent/AU2003294488B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006510619A5 (enExample) | ||
| JP2005512507A5 (enExample) | ||
| US11479880B2 (en) | Fibronectin type III domain based scaffold compositions, methods and uses | |
| US6168791B1 (en) | Antibodies that bind immunomodulators | |
| US7252971B2 (en) | IL-23p40 specific immunoglobulin derived proteins | |
| US8293482B2 (en) | Fibronectin type III domain based scaffold compositions, methods and uses | |
| EP0966300B1 (en) | Treatment of rheumatoid arthritis with antibody anti ifn gamma | |
| IL90990A (en) | Pharmaceuticals and diagnostic preparations containing monoclonal antibodies that react with catechin and a series of cells for their production | |
| WO2004003147A2 (en) | Cngh0004 polypeptides, antibodies, compositions, methods and uses | |
| WO2005005604A2 (en) | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses | |
| WO2006039470A2 (en) | Anti- amyloid antibodies, compositions, methods and uses | |
| JP2003507364A5 (enExample) | ||
| RU97101868A (ru) | Иммуномодуляторы | |
| BRPI0113420B1 (pt) | Anticorpos para il-1beta humano | |
| US20050266005A1 (en) | Methods and compositions for treating IL-3 related pathologies | |
| JP2011500059A (ja) | ヒト抗アミロイド抗体、組成物、方法及び使用 | |
| JP2012504602A5 (enExample) | ||
| EP1684703A2 (en) | Methods and compositions for treating mcp-1 related pathologies | |
| WO1984004172A1 (en) | Monoclonal antibodies to human immune interferon | |
| US20070160606A1 (en) | Treating renal cell carcinoma with an anti-TNF human antibody or fragment | |
| WO2008076784A2 (en) | Methods and compositions for treating il-4 or il-13 related fibrosis related pathologies | |
| US20060246070A1 (en) | Methods and compositions for treating renal cell carcinoma related pathologies | |
| JP2003523186A5 (enExample) | ||
| WO1995027509A1 (en) | Remedy for diseases characterized by abnormal accumulation or activation of leukocyte | |
| CN1056245A (zh) | 含有bcrf1拮抗物的药物组合物的制备方法 |